Efficacy of accelerated vaccination against Hbv to achieve antibody formation in multiple sclerosis patients receiving anti-Cd20 therapy

Efficacy of accelerated vaccination against Hbv to achieve antibody formation in multiple sclerosis patients receiving anti-Cd20 therapy

Aim: Ocrelizumab is a monoclonal antibody that has been approved for use in both relapsing–remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Since ocrelizumab acts on B cells, it also affects humoral immunity, thus reducing the vaccine response. In this study, we...

Full description

Bibliographic Details
Main Authors: Emine Rabia Koc, Omer Faruk Turan, Furkan Saridas, Bedirhan Menguc, Sema Nur Minaz, Guven Ozkaya
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Annals of Indian Academy of Neurology
Subjects:
accelerated vaccination
anti-cd-20 therapy
antibody response
hbv serostatus
multiple sclerosis
Online Access:http://www.annalsofian.org/article.asp?issn=0972-2327;year=2023;volume=26;issue=5;spage=697;epage=701;aulast=Koc

Internet

http://www.annalsofian.org/article.asp?issn=0972-2327;year=2023;volume=26;issue=5;spage=697;epage=701;aulast=Koc

Similar Items